Press Releases

01.14.2021

Pfizer’s XALKORI® (crizotinib) Approved by FDA for ALK-positive Anaplastic Large Cell Lymphoma in Children and Young Adults

01.12.2021

Pfizer Invests $120 Million in Biotechnology Innovation Through the Pfizer Breakthrough Growth Initiative

01.10.2021

Codex DNA Signs Early Access Collaboration and Licensing Agreement with Pfizer to FurtherDevelop CodexDNA’s Novel Enzymatic DNA Synthesis Technology for Pfizer’s use in its Research and Development ofmRNA-based Vaccines and Biotherapies

01.07.2021

Pfizer Doses First Participant in Phase 3 Study for Duchenne Muscular Dystrophy Investigational Gene Therapy

01.05.2021

Pfizer Invites Public to Listen to Two Webcasts of Pfizer Discussions at Healthcare Conference

01.04.2021

US FDA Accepts Regulatory Submission from Pfizer and OPKO for Review of Somatrogon to Treat Pediatric Patients with Growth Hormone Deficiency

12.29.2020

Pfizer and BioNTech to Supply the European Union with 100 Million Additional Doses of COMIRNATY®

12.28.2020

LORBRENA® (lorlatinib) sNDA in Previously Untreated ALK-Positive Lung Cancer Accepted for Priority Review by U.S. FDA

12.28.2020

Myovant Sciences and Pfizer Announce Collaboration to Develop and Commercialize Relugolix in Oncology and Women's Health

12.23.2020

Pfizer and BioNTech to Supply the U.S. with 100 Million Additional Doses of COVID-19 Vaccine

12.22.2020

Pfizer Invites Public to View and Listen to Webcast of February 2 Conference Call with Analysts

12.21.2020

Pfizer and BioNTech Receive Authorization in the European Union for COVID-19 Vaccine